Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer

Expert Opinion on Drug Delivery

Volumn 7, Issue 10, 2010, Pages 1159-1173

  Wang, Bin ^a   Rosano, Jenna M ^a   Cheheltani, Rabe'E ^a   Achary, Mohan P ^b   Kiani, Mohammad F ^a,b  

^a Temple University   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoresistance; Multi drug therapy; Nanoparticles; Targeted drug delivery

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; ANASTROZOLE; APTAMER; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CAPECITABINE; CARRIER PROTEIN; COMBRETASTATIN; CT 2106; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG CARRIER; FOLIC ACID; FULVESTRANT; GENEXOL PM; GLYCOPROTEIN P; IMMUNOLIPOSOME; LETROZOLE; LIPOPLATIN; LIPOSOME; MICROTUBULE ASSOCIATED PROTEIN 4; MYOCET M; NANOPARTICLE; NANOTUBE; NK 012; PACLITAXEL; PACLITAXEL POLIGLUMEX; PK 1; POLYMER; QUANTUM DOT; RALOXIFENE; SYNTHETIC PEPTIDE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST TUMOR; CLINICAL TRIAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG CARRIERS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; PARTICLE SIZE; TREATMENT OUTCOME;

EID: 77957065782     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.513968     Document Type: Review

References (120)

1. Hassett MJ, OMalley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117
2. Farquhar CM, Marjoribanks J, Lethaby A, Basser R. High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 2007;33:325-337
3. Bai Z, Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim) 2009;342:133-149
4. Trompier D, Chang XB, Barattin R, et al. Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 2004;64:4950-4956
5. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424
6. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30
7. Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 2006;239:168-182
8. Sauna ZE, Smith MM, Muller M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001;33:481-491
9. Dexter DW, Reddy RK, Geles KG, et al. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 1998;4:1533-1542
10. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003;10:43-73
11. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302
12. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-15670
13. Ifergan I, Shafran A, Jansen G, et al. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 2004;279:25527-25534
14. Imai Y, Asada S, Tsukahara S, et al. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003;64:610-618
15. Imai Y, Ishikawa E, Asada S, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 2005;65:596-604
16. Wang Y, Cabral F. Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta 2005;1744:245-255
17. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-17125
18. Zhang CC, Yang JM, White E, et al. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998;16:1617-1624
19. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-935
20. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-2925
21. Richardson ME, Siemann DW. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int J Radiat Oncol Biol Phys 1997;39:789-795 .. A good review of the impact of tumor heterogeneity on drug resistance.
22. Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793-4807
23. Normanno N, Morabito A, De LA, et al. Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 2009;16:675-702
24. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-679
25. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-829
26. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220:263-280
27. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008;26:2813-2820
28. Charafe-Jauffret E, Monville F, Ginestier C, et al. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008;75:75-84
29. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813
30. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007;117:3155-3163
31. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-171
32. Niemeyer CM. Semi-synthetic nucleic acid-protein conjugates: applications in life sciences and nanobiotechnology. J Biotechnol 2001;82:47-66
33. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007;2:47-52
34. Weissleder R, Kelly K, Sun EY, et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005;23:1418-1423
35. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286
36. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-3756
37. Gaur U, Sahoo SK, De TK, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000;202:1-10
38. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-763
39. Kannagi R, Izawa M, Koike T, et al. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004;95:377-384
40. Yamazaki N, Kojima S, Bovin NV, et al. Endogenous lectins as targets for drug delivery. Adv Drug Deliv Rev 2000;43:225-244
41. Kornfeld S, Rogers J, Gregory W. The nature of the cell surface receptor site for Lens culinaris phytohemagglutinin. J Biol Chem 1971;246:6581-6586
42. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-1676
43. Stewart FA, Dorr W. Milestones in normal tissue radiation biology over the past 50 years: from clonogenic cell survival to cytokine networks and back to stem cell recovery. Int J Radiat Biol 2009;85:574-586
44. McDonald SA, Graham TA, Schier S, et al. Stem cells and solid cancers. Virchows Arch 2009;455:1-13
45. Fahmy TM, Fong PM, Park J, et al. Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J 2007;9:E171-80
46. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2:369-381
47. Liu J, Li J, Rosol TJ, et al. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol 2007;52:4739-4747
48. Au L, Zheng D, Zhou F, et al. A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. ACS Nano 2008;2:1645-1652
49. Noble CO, Guo Z, Hayes ME, et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 2009;64:741-751
50. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127-1141
51. Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 2004;56:1161-1176
52. Pattillo CB, Sari-Sarraf F, Nallamothu R, et al. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res 2005;22:1117-1120
53. Khang D, Kim SY, Liu-Snyder P, et al. Enhanced fibronectin adsorption on carbon nanotube/poly(carbonate) urethane: independent role of surface nano-roughness and associated surface energy. Biomaterials 2007;28:4756-4768
54. Green LS, Jellinek D, Bell C, et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995;2:683-695
55. Harding JA, Engbers CM, Newman MS, et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1997;1327:181-192
56. Pattillo CB, Venegas B, Donelson FJ, et al. Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors. Pharm Res 2009;26:1093-1100
57. Scott RC, Wang B, Nallamothu R, et al. Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng 2007;96(4):795-802
58. Scott R, Sun Y, Nallamothu R, et al. Targeting model drug carriers and immunoliposomes to hypoxic areas in the infarcted heart. [abstract]. Proc. Fall BMES MTG 2004
59. Scott RC, Crabbe D, Krynska B, et al. Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv 2008;5:459-470
60. Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods Mol Biol 2010;624:249-265
61. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803
62. Wartlick H, Michaelis K, Balthasar S, et al. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004;12:461-471
63. Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/ DNA complexes used in cell transfection. Biochemistry 1996;35:5616-5623
64. Sakurai F, Inoue R, Nishino Y, et al. Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. J Control Release 2000;66:255-269
65. Sheff D. Endosomes as a route for drug delivery in the real world. Adv Drug Deliv Rev 2004;56:927-930
66. Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24:2773-2778
67. Jones RL, Berry GJ, Rubens RD, Miles DW. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol 2004;5:575-577
68. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003;3:319-328
69. Lasic DD, Vallner JJ, Working PK. Sterically stabilized liposomes in cancer therapy and gene delivery. Curr Opin Mol Ther 1999;1:177-185
70. Nielsen UB, Kirpotin DB, Pickering EM, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002;1591:109-118
71. Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer 2007;96:1315-1319
72. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631-11638
73. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008;41:60-68
74. Kam NW, OConnell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA 2005;102:11600-11605
75. Marx V. Poised to branch out. Nat Biotechnol 2008;26:729-732
76. Usui Y, Aoki K, Narita N, et al. Carbon nanotubes with high bone-tissue compatibility and bone-formation acceleration effects. Small 2008;4:240-246
77. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1-16
78. Rhyner MN, Smith AM, Gao X, et al. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) 2006;1:209-217
79. Xing Y, Chaudry Q, Shen C, et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2007;2:1152-1165
80. Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969-976
81. Anas A, Okuda T, Kawashima N, et al. Clathrin-mediated endocytosis of quantum dot-peptide conjugates in living cells. ACS Nano 2009;3:2419-2429
82. Lidke DS, Nagy P, Heintzmann R, et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 2004;22:198-203
83. Xiao Y, Gao X. Use of IgY antibodies and semiconductor nanocrystal detection in cancer biomarker quantitation. Biomark Med 2010;4:227-239
84. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett 2008;8:2851-2857
85. Bailey RE, Nie S. Alloyed semiconductor quantum dots: tuning the optical properties without changing the particle size. J Am Chem Soc 2003;125:7100-7106
86. Kim S, Fisher B, Eisler HJ, Bawendi M. Type-II quantum dots: CdTe/CdSe(core/ shell) and CdSe/ZnTe(core/shell) heterostructures. J Am Chem Soc 2003;125:11466-11467
87. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204
88. Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010;255:415-425
89. Pesic M, Podolski A, Rakic L, Ruzdijic S. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil. Invest New Drugs 2010;28:482-492
90. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
91. Vujaskovic Z, Kim DW, Jones E, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010;26:514-521
92. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337
93. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-1986
94. Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol 2008;6:41-48
95. Reichardt P, von MG, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda()) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233
96. Jones S, Holmes FA, OShaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009;27:1177-1183
97. Fumoleau P, Cortes-Funes H, Taleb AB, et al. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol 2009;32(4):375-380
98. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388
99. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717
100. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741
101. Grady D, Cauley JA, Stock JL, et al. Effect of Raloxifene on all-cause mortality. Am J Med 2010;123:469-477
102. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-4535
103. Neven P, Paridaens R, Pelgrims G, et al. Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 2008;109:59-65
104. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;79:730-739
105. Aihara T, Takatsuka Y, Ohsumi S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat 2010;121:379-387
106. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-2109
107. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-124
108. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221
109. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol 2010;33:186-195
110. Available from: http://clinicaltrials.gov/ ct2/show/NCT00507429 [Last accessed 20 July 2010]
111. Pili R, Rosenthal MA, Mainwaring PN, et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4- acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010;16:2906-2914
112. Lin NU, Parker LM, Come SE, et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007;25:369-375
113. Homsi J, Simon GR, Garrett CR, et al. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 2007;13:5855-5861
114. Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009;34:1629-1636
115. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 2010; In press
116. Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108:241-250
117. OBrien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449
118. Batist G, Harris L, Azarnia N, et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006;17:587-595
119. Lim WT, Tan EH, Toh CK, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 2010;21:382-388
120. Boulikas T. Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009;18:1197-1218